Log in to save to my catalogue

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-...

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_70705369

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

About this item

Full title

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2007-07, Vol.370 (9581), p.39-48

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background TMC125 (etravirine) is a non-nucleoside reverse-transcriptase inhibitor (NNRTI) with activity against NNRTI-resistant HIV-1 in phase IIb trials. The aim of DUET-2 is to examine the efficacy, tolerability, and safety of TMC125 in treatment-experienced patients. Methods In this continuing randomised, double-blind, placebo-controlle...

Alternative Titles

Full title

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_70705369

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_70705369

Other Identifiers

ISSN

0140-6736,1474-547X

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(07)61048-4

How to access this item